CTLA-4 (CD152): A versatile receptor for immune-based therapy

Brunet, 1987, A new member of the immunoglobulin superfamily--CTLA-4, Nature, 328, 267, 10.1038/328267a0 Harper, 1991, CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location, J. Immunol., 147, 1037, 10.4049/jimmunol.147.3.1037 Hansen, 1980, Monoclonal antibodies identifying a novel T-cell antigen and Ia antigens of human lymphocytes, Immungenetics, 10, 247, 10.1007/BF01561573 Harding, 1992, CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature, 356, 607, 10.1038/356607a0 Beyersdorf, 2015, CD28 co-stimulation in T-cell homeostasis: a recent perspective, Immunotargets Ther., 4, 111 Linsley, 1991, CTLA-4 is a second receptor for the B cell activation antigen B7, J. Exp. Med., 174, 561, 10.1084/jem.174.3.561 Linsley, 1994, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, Immunity, 1, 793, 10.1016/S1074-7613(94)80021-9 Collins, 2002, The interaction properties of costimulatory molecules revisited, Immunity, 17, 201, 10.1016/S1074-7613(02)00362-X Linsley, 1992, Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule, Science, 257, 792, 10.1126/science.1496399 Webb, 1996, Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2, Eur. J. Immunol., 26, 2320, 10.1002/eji.1830261008 Freeman, 1992, CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production, J. Immunol., 149, 3795, 10.4049/jimmunol.149.12.3795 Lindsten, 1993, Characterization of CTLA-4 structure and expression on human T cells, J. Immunol., 151, 3489, 10.4049/jimmunol.151.7.3489 Linsley, 1992, Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes, J. Exp. Med., 176, 1595, 10.1084/jem.176.6.1595 Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X Maszyna, 2003, Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes, J. Immunol., 171, 3459, 10.4049/jimmunol.171.7.3459 Pandiyan, 2007, High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4), J. Immunol., 178, 2132, 10.4049/jimmunol.178.4.2132 Tagami, 2000, Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4, J. Exp. Med., 192, 303, 10.1084/jem.192.2.303 Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J. Exp. Med., 182, 459, 10.1084/jem.182.2.459 Brunner, 1999, CTLA-4-Mediated inhibition of early events of T cell proliferation, J. Immunol., 162, 5813, 10.4049/jimmunol.162.10.5813 Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6 Waterhouse, 1995, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985, 10.1126/science.270.5238.985 Chambers, 1996, The role of CTLA-4 in the regulation and initiation of T-cell responses, Immunol. Rev., 153, 27, 10.1111/j.1600-065X.1996.tb00919.x Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Kwon, 1997, Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer, Proc. Natl. Acad. Sci. U.S.A., 94, 8099, 10.1073/pnas.94.15.8099 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 Dariavach, 1988, Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains, Eur. J. Immunol., 18, 1901, 10.1002/eji.1830181206 Ling, 1999, Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders, Genomics, 60, 341, 10.1006/geno.1999.5930 Polymeropoulos, 1991, Dinucleotide repeat polymorphism at the human CTLA4 gene, Nucleic Acids Res., 19, 4018 Deichmann, 1996, An mse I RFLP in the human CTLA4 promotor, Biochem. Biophys. Res. Commun., 225, 817, 10.1006/bbrc.1996.1256 Nistico, 1996, The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes, Belgian Diabetes Registry. Hum Mol Genet, 5, 1075, 10.1093/hmg/5.7.1075 Chen, 2017, Investigation of Cytotoxic T-lymphocyte antigen-4 polymorphisms in non-small cell lung cancer: a case-control study, Oncotarget, 8, 76634, 10.18632/oncotarget.20638 Gibson, 2007, Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter, J. Immunol., 179, 3831, 10.4049/jimmunol.179.6.3831 Finn, 1997, Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability, J. Immunol., 158, 4074, 10.4049/jimmunol.158.9.4074 Li, 2013, Regulation of cytotoxic T lymphocyte antigen 4 by cyclic AMP, Am. J. Respir. Cell Mol. Biol., 48, 63, 10.1165/rcmb.2012-0155OC Krummel, 1996, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells, J. Exp. Med., 183, 2533, 10.1084/jem.183.6.2533 Walunas, 1996, CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med., 183, 2541, 10.1084/jem.183.6.2541 Egen, 2002, Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength, Immunity, 16, 23, 10.1016/S1074-7613(01)00259-X Pandiyan, 2004, CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function, J. Exp. Med., 199, 831, 10.1084/jem.20031058 Zhu, 2011, Cell surface signaling molecules in the control of immune responses: a tide model, Immunity, 34, 466, 10.1016/j.immuni.2011.04.008 Knieke, 2009, CD152 (CTLA-4) determines CD4 T cell migration in vitro and in vivo, PLoS One, 4, e5702, 10.1371/journal.pone.0005702 Chan, 2014, Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation, Genes Immun., 15, 25, 10.1038/gene.2013.57 Pick, 2014, CTLA-4 (CD152) enhances the Tc17 differentiation program, Eur. J. Immunol., 44, 2139, 10.1002/eji.201343497 Alegre, 1998, Expression and function of CTLA-4 in Th1 and Th2 cells, J. Immunol., 161, 3347, 10.4049/jimmunol.161.7.3347 Krummey, 2014, Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade, J. Immunol., 192, 2495, 10.4049/jimmunol.1301332 Jago, 2004, Differential expression of CTLA-4 among T cell subsets, Clin. Exp. Immunol., 136, 463, 10.1111/j.1365-2249.2004.02478.x Read, 2006, Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo, J. Immunol., 177, 4376, 10.4049/jimmunol.177.7.4376 Verhagen, 2014, Ctla-4 modulates the differentiation of inducible Foxp3+ Treg cells but IL-10 mediates their function in experimental autoimmune encephalomyelitis, PLoS One, 9, 10.1371/journal.pone.0108023 Tang, 2008, CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis, J. Immunol., 181, 1806, 10.4049/jimmunol.181.3.1806 Kolar, 2009, CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice, Arthritis Rheum., 60, 123, 10.1002/art.24181 Jain, 2010, Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity, Proc. Natl. Acad. Sci. U.S.A., 107, 1524, 10.1073/pnas.0910341107 Matheu, 2015, Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming, Nat. Commun., 6, 6219, 10.1038/ncomms7219 Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062 Fontenot, 2005, Regulatory T cell lineage specification by the forkhead transcription factor foxp3, Immunity, 22, 329, 10.1016/j.immuni.2005.01.016 Linsley, 1996, Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement, Immunity, 4, 535, 10.1016/S1074-7613(00)80480-X Iida, 2000, Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells, J. Immunol., 165, 5062, 10.4049/jimmunol.165.9.5062 Valk, 2006, T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor, Immunity, 25, 807, 10.1016/j.immuni.2006.08.024 Darlington, 2002, Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation, J. Exp. Med., 195, 1337, 10.1084/jem.20011868 Qureshi, 2012, Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation, J. Biol. Chem., 287, 9429, 10.1074/jbc.M111.304329 Shiratori, 1997, Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2, Immunity, 6, 583, 10.1016/S1074-7613(00)80346-5 Schneider, 1999, Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2, J. Immunol., 163, 1868, 10.4049/jimmunol.163.4.1868 Kouki, 2000, CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease, J. Immunol., 165, 6606, 10.4049/jimmunol.165.11.6606 Brunner-Weinzierl, 2004, Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases, Arthritis Res. Ther., 6, 45, 10.1186/ar1158 Luna, 2010, Female-biased incidence of experimental autoimmune encephalomyelitis reflects sexually dimorphic expression of surface CTLA-4 (CD152) on T lymphocytes, Gend. Med., 7, 296, 10.1016/j.genm.2010.08.005 Ise, 2010, CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms, Nat. Immunol., 11, 129, 10.1038/ni.1835 Schwartz, 2001, Structural basis for co-stimulation by the human CTLA-4/B7-2 complex, Nature, 410, 604, 10.1038/35069112 Stamper, 2001, Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses, Nature, 410, 608, 10.1038/35069118 Pentcheva-Hoang, 2004, B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse, Immunity, 21, 401, 10.1016/j.immuni.2004.06.017 Yokosuka, 2010, Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation, Immunity, 33, 326, 10.1016/j.immuni.2010.09.006 Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947 Rudd, 2003, Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling, Nature Rev Immunol, 3, 544, 10.1038/nri1131 Schneider, 1995, CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells, J. Exp. Med., 181, 351, 10.1084/jem.181.1.351 Liu, 2008, CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization, Eur. J. Immunol., 38, 40, 10.1002/eji.200737423 Wei, 2007, CTL-associated antigen-4 ligation induces rapid T cell polarization that depends on phosphatidylinositol 3-kinase, Vav-1, Cdc42, and myosin light chain kinase, J. Immunol., 179, 400, 10.4049/jimmunol.179.1.400 Schneider, 2005, CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function, Proc. Natl. Acad. Sci. U.S.A., 102, 12861, 10.1073/pnas.0505802102 Guntermann, 2002, CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases, J. Immunol., 168, 4420, 10.4049/jimmunol.168.9.4420 Schneider, 2006, Reversal of the TCR stop signal by CTLA-4, Science, 313, 1972, 10.1126/science.1131078 Chuang, 2000, The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A, Immunity, 13, 313, 10.1016/S1074-7613(00)00031-5 Lee, 1998, Molecular basis of T cell inactivation by CTLA-4, Science, 282, 2263, 10.1126/science.282.5397.2263 Kong, 2014, Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function, Nat. Immunol., 15, 465, 10.1038/ni.2866 Chambers, 1997, Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells, Immunity, 7, 885, 10.1016/S1074-7613(00)80406-9 Khattri, 1999, Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses, J. Immunol., 162, 5784, 10.4049/jimmunol.162.10.5784 Tai, 2007, Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation, Proc. Natl. Acad. Sci. U.S.A., 104, 13756, 10.1073/pnas.0706509104 Klocke, 2016, Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood, Proc. Natl. Acad. Sci. U.S.A., 113, E2383, 10.1073/pnas.1603892113 Paterson, 2015, Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity, J. Exp. Med., 212, 1603, 10.1084/jem.20141030 Kuehn, 2014, Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4, Science, 345, 1623, 10.1126/science.1255904 Kotsa, 1997, A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism, Clin. Endocrinol. (Oxf), 46, 551, 10.1046/j.1365-2265.1997.1710996.x Snook, 2003, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease, Nature, 423, 506, 10.1038/nature01621 Zhai, 2013, CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis, Mol. Biol. Rep., 40, 5213, 10.1007/s11033-012-2125-7 Magistrelli, 1999, A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells, Eur. J. Immunol., 29, 3596, 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y Oaks, 2000, Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease, J. Immunol., 164, 5015, 10.4049/jimmunol.164.10.5015 Simone, 2014, The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses, Biomed Res. Int., 2014, 10.1155/2014/215763 Vijayakrishnan, 2004, An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells, Immunity, 20, 563, 10.1016/S1074-7613(04)00110-4 Stumpf, 2013, The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes, J. Immunol., 190, 961, 10.4049/jimmunol.1201362 Liu, 2012, Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity, J. Immunol., 188, 155, 10.4049/jimmunol.1102042 Chikuma, 2005, B7-independent inhibition of T cells by CTLA-4, J. Immunol., 175, 177, 10.4049/jimmunol.175.1.177 Masteller, 2000, Structural analysis of CTLA-4 function in vivo, J. Immunol., 164, 5319, 10.4049/jimmunol.164.10.5319 Bachmann, 1999, Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous, J. Immunol., 163, 1128, 10.4049/jimmunol.163.3.1128 Tivol, 2002, Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4, J. Immunol., 169, 1852, 10.4049/jimmunol.169.4.1852 Grohmann, 2002, CTLA-4-Ig regulates tryptophan catabolism in vivo, Nat. Immunol., 3, 1097, 10.1038/ni846 Verhagen, 2009, Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease, Proc. Natl. Acad. Sci. U.S.A., 106, 3306, 10.1073/pnas.0803186106 Gu, 2012, Trogocytosis of CD80 and CD86 by induced regulatory T cells, Cell. Mol. Immunol., 9, 136, 10.1038/cmi.2011.62 Devarajan, 2014, Opposing effects of CTLA4 insufficiency on regulatory versus conventional T cells in autoimmunity converge on effector memory in target tissue, J. Immunol., 193, 4368, 10.4049/jimmunol.1400876 Rudolph, 2011, Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo, J. Immunol., 186, 5580, 10.4049/jimmunol.1003381 Tai, 2012, Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells, Blood, 119, 5155, 10.1182/blood-2011-11-388918 Maschmeyer, 2011, CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells, Clin. Exp. Rheumatol., 29, 254 Lu, 2012, Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal, Blood, 120, 4560, 10.1182/blood-2012-04-421420 Corse, 2012, Cutting edge: CTLA-4 on effector T cells inhibits in, Trans. J Immunol, 189, 1123, 10.4049/jimmunol.1200695 Wang, 2012, Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells, J. Immunol., 189, 1118, 10.4049/jimmunol.1200972 Chambers, 1998, Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells, Eur. J. Immunol., 28, 3137, 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X Hegel, 2009, CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin, Eur. J. Immunol., 39, 883, 10.1002/eji.200838770 Kaech, 2001, Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells, Nat. Immunol., 2, 415, 10.1038/87720 van Stipdonk, 2001, Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation, Nat. Immunol., 2, 423, 10.1038/87730 Best, 2013, Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation, Nat. Immunol., 14, 404, 10.1038/ni.2536 Hoff, 2010, CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch, Mol. Immunol., 47, 1875, 10.1016/j.molimm.2010.03.017 Lingel, 2017, CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation, Cell Death Differ., 24, 1739, 10.1038/cdd.2017.102 Arra, 2017, The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs, Oncoimmunology, 6, 10.1080/2162402X.2016.1273300 Zumwalde, 2013, ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation, J. Immunol., 191, 3681, 10.4049/jimmunol.1201954 Gerard, 2013, Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells, Nat. Immunol., 14, 356, 10.1038/ni.2547 Krummel, 2018, Paracrine costimulation of IFN-gamma signaling by integrins modulates CD8 T cell differentiation, Proc. Natl. Acad. Sci. U.S.A., 115, 11585, 10.1073/pnas.1804556115 Homann, 2006, Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity, J. Virol., 80, 270, 10.1128/JVI.80.1.270-280.2006 Knoerzer, 1995, Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig, J. Clin. Invest., 96, 987, 10.1172/JCI118146 Khoury, 1995, CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system, J. Immunol., 155, 4521, 10.4049/jimmunol.155.10.4521 Cutolo, 2013, Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis, Autoimmun. Rev., 12, 758, 10.1016/j.autrev.2013.01.001 Platt, 2010, Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells, J. Immunol., 185, 1558, 10.4049/jimmunol.1001311 Bonelli, 2013, Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis, Arthritis Rheum., 65, 599, 10.1002/art.37787 Bonelli, 2016, Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis, Rheumatology Oxford (Oxford), 55, 710, 10.1093/rheumatology/kev403 Holt, 2017, Shevach EM. TCR signaling and CD28/CTLA-4 signaling cooperatively modulate t regulatory cell homeostasis, J. Immunol., 198, 1503, 10.4049/jimmunol.1601670 Patakas, 2016, Abatacept inhibition of t cell priming in mice by induction of a unique transcriptional profile that reduces their ability to activate antigen-presenting cells, ., 68, 627 Kormendy, 2013, Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis, Arthritis Rheum., 65, 81, 10.1002/art.37714 Whitfield, 2017, Interference of the t cell and antigen-presenting cell costimulatory pathway using CTLA4-Ig (Abatacept) prevents staphylococcal enterotoxin B pathology, J. Immunol., 198, 3989, 10.4049/jimmunol.1601525 Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci. U.S.A., 100, 8372, 10.1073/pnas.1533209100 Kwon, 1999, Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 96, 15074, 10.1073/pnas.96.26.15074 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371, 2189, 10.1056/NEJMoa1406498 Ilyas, 2015, Landscape of Tumor Antigens in T Cell Immunotherapy, J. Immunol., 195, 5117, 10.4049/jimmunol.1501657 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093 Ramagopal, 2017, Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab, Proc. Natl. Acad. Sci. U.S.A., 114, E4223, 10.1073/pnas.1617941114 Thaventhiran, 2012, Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell, Proc. Natl. Acad. Sci. U.S.A., 109, E2223, 10.1073/pnas.1209115109 Paine, 2012, IL-2 upregulates CD86 expression on human CD4(+) and CD8(+) T cells, J. Immunol., 188, 1620, 10.4049/jimmunol.1100181 Knieke, 2012, Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation, PLoS One, 7, 10.1371/journal.pone.0031391 Downey, 2008, TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice, Immunol. Lett., 115, 70, 10.1016/j.imlet.2007.09.004 Brunner-Weinzierl, 2018, CTLA-4 and PD-1 control of T-Cell motility and migration: implications for tumor immunotherapy, Front. Immunol., 9, 2737, 10.3389/fimmu.2018.02737 Yshii, 2016, CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model, Brain, 139, 2923, 10.1093/brain/aww225 Ruocco, 2012, Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects, J. Clin. Invest., 122, 3718, 10.1172/JCI61931 Hadrup, 2013, Effector CD4 and CD8 T cells and their role in the tumor microenvironment, Cancer Microenviron., 6, 123, 10.1007/s12307-012-0127-6 Wei, 2017, Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade, Cell, 170, 1120, 10.1016/j.cell.2017.07.024 Fehlings, 2017, Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells, Nat. Commun., 8, 562, 10.1038/s41467-017-00627-z Kvistborg, 2014, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Sci. Transl. Med., 6, 10.1126/scitranslmed.3008918 Martinez-Lostao, 2015, How do cytotoxic lymphocytes kill Cancer cells?, Clinical Cancer Res, 21, 5047, 10.1158/1078-0432.CCR-15-0685 Wherry, 2007, Molecular signature of CD8+ T cell exhaustion during chronic viral infection, Immunity, 27, 670, 10.1016/j.immuni.2007.09.006 Baitsch, 2011, Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients, J. Clin. Invest., 121, 2350, 10.1172/JCI46102 Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792 Patsoukis, 2015, PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation, Nat. Commun., 6, 6692, 10.1038/ncomms7692 Cammann, 2016, Early changes in the metabolic profile of activated CD8(+) T cells, BMC Cell Biol., 17, 28, 10.1186/s12860-016-0104-x Liakou, 2008, CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients, Proc. Natl. Acad. Sci. U.S.A., 105, 14987, 10.1073/pnas.0806075105 Chen, 2009, Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues, Proc. Natl. Acad. Sci. U.S.A., 106, 2729, 10.1073/pnas.0813175106 Du, 2018, A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy, Cell Res., 28, 416, 10.1038/s41422-018-0011-0 Selby, 2013, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells, Cancer Immunol. Res., 1, 32, 10.1158/2326-6066.CIR-13-0013 Simpson, 2013, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J. Exp. Med., 210, 1695, 10.1084/jem.20130579 Sharma, 2019, Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory t cells (Tregs) in human cancers, Clinical Cancer Res, 25, 1233, 10.1158/1078-0432.CCR-18-0762 Arce, 2018, Fc effector function contributes to the activity of human Anti-CTLA-4 antibodies, Cancer Cell, 33, 649, 10.1016/j.ccell.2018.02.010 Tang, 2004, Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function, Eur. J. Immunol., 34, 2996, 10.1002/eji.200425143 Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, J. Exp. Med., 206, 1717, 10.1084/jem.20082492 Keir, 2006, Tissue expression of PD-L1 mediates peripheral T cell tolerance, J. Exp. Med., 203, 883, 10.1084/jem.20051776 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm730 Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc. Natl. Acad. Sci. U.S.A., 107, 4275, 10.1073/pnas.0915174107 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369, 122, 10.1056/NEJMoa1302369 Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N. Engl. J. Med., 377, 1345, 10.1056/NEJMoa1709684 Fan, 2014, Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy, J. Exp. Med., 211, 715, 10.1084/jem.20130590 Ariyan, 2018, Robust antitumor responses result from local chemotherapy and CTLA-4 blockade, Cancer Immunol. Res., 6, 189, 10.1158/2326-6066.CIR-17-0356 Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107 Schneider, 2014, Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4, Front. Immunol., 5, 619, 10.3389/fimmu.2014.00619